Send to

Choose Destination
Trends Mol Med. 2003 Jan;9(1):2-4.

Nanoparticle-mediated gene delivery to tumour neovasculature.

Author information

Cell Adhesion and Disease Laboratory, Cancer Research UK, Richard Dimbleby Department of Cancer Research, St. Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK.


The alpha(v)beta(3) integrin is a potential pharmacological target for anti-angiogenic therapy. A recent report describes the use of alpha(v)beta(3)-targeted nanoparticles to deliver a gene to tumour vasculature selectively. This resulted in substantial tumour regression in several experimental mouse tumour models. Hence, this approach has great potential for the treatment of human cancer.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center